Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antipsychotic medication |
| gptkbp:approvalYear |
2009
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
N05AH05
|
| gptkbp:bioavailability |
35% (sublingual)
|
| gptkbp:brand |
Saphris
Sycrest |
| gptkbp:CASNumber |
65576-45-6
|
| gptkbp:category |
antipsychotics
dopamine antagonists serotonin receptor antagonists organon compounds |
| gptkbp:chemicalClass |
dibenzoxepinopyrrole
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:developedBy |
gptkb:Organon
|
| gptkbp:eliminationHalfLife |
24 hours
|
| gptkbp:form |
sublingual tablet
transdermal patch |
| gptkbp:hasMolecularFormula |
C17H16ClNO
|
| https://www.w3.org/2000/01/rdf-schema#label |
asenapine
|
| gptkbp:IUPACName |
(3aRS,12bRS)-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
|
| gptkbp:KEGGID |
D08913
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
serotonin-dopamine antagonist
|
| gptkbp:meltingPoint |
123–125 °C
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
B3 (Australia) |
| gptkbp:proteinBinding |
95%
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201197
184646 213026 DB06216 |
| gptkbp:routeOfAdministration |
transdermal
sublingual |
| gptkbp:sideEffect |
dizziness
weight gain extrapyramidal symptoms somnolence increased appetite akathisia oral hypoesthesia |
| gptkbp:smiles |
CC1=CC2=C(C=C1)OCC3=C2N(C4=CC=CC=C34)Cl
|
| gptkbp:synonym |
asenapine maleate
|
| gptkbp:UNII |
J3GN7L2A3E
|
| gptkbp:usedFor |
bipolar disorder
schizophrenia |
| gptkbp:bfsParent |
gptkb:N05AX
gptkb:5-HT2C_receptor |
| gptkbp:bfsLayer |
7
|